OS by FLT3-ITD, NPM1 mutation, and age. (Left) Aged younger than 60 years. (Right) Aged 60 to 74 years. Log rank analyses of survival in patients younger than 60 years (left): comparison of all 4 subsets (P = .00027); no FLT3-ITD/NPM1 mutated (group A) vs double-negative (group B; P = .049); FLT3-ITD/NPM1 mutated (group C) vs FLT3-ITD/NPM1 wild type (group D; P = .62); group A vs C (P = .0005); group A vs D (P = .0004); group B vs C (P = .007); group B vs D (P = .018). Patients aged 60 to 74 years (right): all 4 subsets (P < .0001, group A vs B (P < .0001), group C vs D (P = .049), group A vs C (P = .073), group A vs D (P < .0001), group B vs C (P = .10), and group B vs D (P = .37).